Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation, potential implications for COX-2 inhibition

Recent increased adverse cardiovascular events observed with selective cyclooxygenase-2 (COX-2) inhibition led to the withdrawal of rofecoxib (Vioxx) and valdecoxib (Bextra), but the mechanisms underlying these atherothrombotic events remain unclear. Prostacyclin is the major endproduct of COX-2 in...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Arehart, Eric, Stitham, Jeremiah, Asselbergs, Folkert W., Douville, Karen, MacKenzie, Todd, Fetalvero, Kristina M., Gleim, Scott, Kasza, Zsolt, Rao, Yamini, Martel, Laurie, Segel, Sharon, Robb, John, Kaplan, Aaron, Simons, Michael, Powell, Richard J., Moore, Jason H., Rimm, Eric B., Martin, Kathleen A., Hwa, John
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2008
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2793685/
https://ncbi.nlm.nih.gov/pubmed/18323528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCRESAHA.107.165936
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller